Temafloxacin
Temafloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair, producing bactericidal effects against a broad spectrum of gram-positive and gram-negative organisms. It was withdrawn from the market in 1992 due to a rare but serious syndrome of hemolytic anemia, hypoglycemia, and coagulopathy (temafloxacin syndrome). Its pharmacological mechanism is similar to other fluoroquinolones but its idiosyncratic toxicity profile led to permanent market withdrawal.
Masse moléculaire
417,4000 g/mol
LogP
0,60
TPSA
72,90 Ų
Règle des 5 de Lipinski
Conforme
Mécanisme d'action
Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.
Structure 2D
Cite this structure
Embed this structure
SMILES
CC1CN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)CCN1
InChI
InChI=1S/C21H18F3N3O3/c1-11-9-26(5-4-25-11)19-8-18-13(7-16(19)24)20(28)14(21(29)30)10-27(18)17-3-2-12(22)6-15(17)23/h2-3,6-8,10-11,25H,4-5,9H2,1H3,(H,29,30)
Molecular Formula
C21H18F3N3O3
HBD / HBA
2 / 9
Liaisons Rotatives
3
Atomes Lourds
30
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
Temafloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair, producing bactericidal effects against a broad spectrum of gram-positive and gram-negative organisms. It was withdrawn from the market in 1992 due to a rare but serious syndrome of hemolytic anemia, hypoglycemia, and coagulopathy (temafloxacin syndrome). Its pharmacological mechanism is similar to other fluoroquinolones but its idiosyncratic toxicity profile led to permanent market withdrawal.
Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.
Yes, Temafloxacin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL277100. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 60021. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="temafloxacin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/temafloxacin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/temafloxacin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/temafloxacin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="temafloxacin"></drugfyi-drug>